Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07176013

Immersive Virtual Reality Meditation in Voice Therapy

Immediate and Cumulative Effects of Meditation on Voice Therapy Using Immersive Virtual Reality (IVR)

Status
Enrolling By Invitation
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Icahn School of Medicine at Mount Sinai · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study aims to explore the feasibility of incorporating regular guided meditations via immersive virtual reality (IVR) at the start of voice therapy sessions to facilitate better learning and retention of treatment. The study will involve 30 participants, and use the TRIPP application with the Meta Quest 2 virtual reality headset, known for its immersive meditation experiences designed to calm or focus the user. The objective is to investigate the immediate effects of meditation/mindfulness in IVR on vocal production, with the goal of improving self-regulation, attentional focus, and reducing vocal hyperfunction. IVR has been utilized in mental health settings and exposure therapy for various conditions, but its application in voice therapy, particularly for anxiety reduction through fully immersive meditation, remains unexplored. The study seeks to determine whether IVR can enhance therapy outcomes by improving engagement, attention, and vocal control in individuals undergoing voice therapy, potentially maximizing treatment gains. Through this research, the aim is to assess the efficacy of IVR in enhancing voice therapy interventions and addressing the unique challenges posed by stress and anxiety in voice users.

Conditions

Interventions

TypeNameDescription
BEHAVIORALVoice therapyAll patients will receive a course of voice therapy as normal.
BEHAVIORALMeditationMeditation at the start of each session. (each session is 30 minutes)
DEVICEVirtual RealityTRIPP application in the Meta Quest 2 Virtual Reality Headset.

Timeline

Start date
2025-09-03
Primary completion
2026-09-30
Completion
2026-12-30
First posted
2025-09-16
Last updated
2026-02-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07176013. Inclusion in this directory is not an endorsement.